Good day, Richard here. As you may know, we're back and we're making new podcasts, but

with work commitments we may not finish a new podcast every week, so we're planning

to hand pick some of our favourite podcast episodes from our back catalogue and republish

them with updated commentary of why we liked each episode and what has changed about

the subjects and the podcast originally aired. The evidence-based supporting a low-carb

ketogenic dietary intervention for type 2 diabetics to treat their disease only grows every

day. In 2014, when I started Kiro, there was just a handful of robust studies that strongly

suggested this approach would work to treat type 2 diabetics and that it would be safe

to do so. Especially with respect to the concerns of a diet that is really quite high in saturated

fat and how that would impact biomarkers of heart disease, I think back then we just had

really the work of Eric Westman showing that, surprisingly, heart disease biomarkers like

HDL cholesterol, the good kind increased and importantly, triglycerides and circulation decreased.

Now, in 2021, we have our positive cornucopia of studies from the long-term open-labeled

controlled clinical trial of Sarah Hullberg showing that type 2 diabetics treated with a ketogenic

diet versus usual care are significantly able to reduce anti-glycemic medications and

significantly improve their glucose control to the point that they would no longer be considered

type 2 diabetics. Another example is a pure study of salimusive looking at correlations in 18

countries of 135,000 subjects showing that high carbohydrate intake was associated with higher

risk of total mortality, whereas total fat and individual types of fat were related to lower

total mortality. Total fat and types of fat were also not associated with cardiovascular disease,

myocardial infarction, or cardiovascular disease mortality, whereas saturated fat surprisingly

had an inverse association with stroke, more saturated fat, less stroke. But one of the most

...